Invesco S&P 500 Equal Weight Health Care ETF (RSPH)
An exchange-traded fund listed on AMEX. A fund is not a company: it has no filed accounts of its own here, and it is never ranked beside companies. Every figure below is market data, with the day it was supplied.
Price
Last close 39.12 USD on Oct 15, 2026. Market data, supplied Oct 15, 2026.
What it costs
| Expense ratio | 0.40% |
| Assets under management | 899.3M USD |
| Net asset value per share | 37.74 USD |
| Inception | Nov 1, 2006 |
| Sponsor | Invesco |
| Asset class | Equity |
| Holdings the fund reports | 61 |
Market data, supplied Oct 15, 2026.
What it holds
The largest 25 by weight of the 65 holdings in the snapshot of Oct 15, 2026. A fund is marked as a fund, and a holding that is not a company's share (a bond, a bill, cash, an option or a swap) is marked as not a company.
| # | Holding | Weight |
|---|---|---|
| 1 | Moderna Inc | 2.64% |
| 2 | Illumina Inc | 2.10% |
| 3 | Mettler-Toledo International Inc | 1.97% |
| 4 | Revvity Inc | 1.94% |
| 5 | Agilent Technologies Inc | 1.90% |
| 6 | Intuitive Surgical Inc | 1.88% |
| 7 | Veeva Systems Inc | 1.80% |
| 8 | AbbVie Inc | 1.79% |
| 9 | HCA Healthcare Inc | 1.76% |
| 10 | Thermo Fisher Scientific Inc | 1.76% |
| 11 | West Pharmaceutical Services Inc | 1.76% |
| 12 | Biogen Inc | 1.75% |
| 13 | Danaher Corp | 1.74% |
| 14 | Centene Corp | 1.73% |
| 15 | McKesson Corp | 1.73% |
| 16 | Amgen Inc | 1.72% |
| 17 | Charles River Laboratories International Inc | 1.71% |
| 18 | Waters Corp | 1.71% |
| 19 | Elevance Health Inc | 1.70% |
| 20 | Eli Lilly & Co | 1.70% |
| 21 | ResMed Inc | 1.69% |
| 22 | Humana Inc | 1.69% |
| 23 | Viatris Inc | 1.67% |
| 24 | Universal Health Services Inc | 1.67% |
| 25 | Gilead Sciences Inc | 1.67% |
Market data, supplied Oct 15, 2026.
Sector weights
| Healthcare | 100.00% |
Market data, supplied Oct 15, 2026.
Country weights
| United States | 96.76% |
| Ireland | 3.24% |
Market data, supplied Oct 15, 2026.
Look-through value
Earnings yield, P/E and book yield of the holdings taken together: n/a. Look-through figures are not measured for this fund yet.